Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Long term AEs in PSMA-TRT

Scott Tagawa, MD, MS, Weill Cornell Medical College, New York Presbyterian Hospital, NY, discusses long-term adverse events (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT). Preliminary studies suggest that long-term toxicity of PSMA-TRT is minimal; most AEs were attributed to alternative etiologies. Prof. Tagawa highlights the importance of including long-term follow-up in future trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 virtual meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.